glp-1 news 2025 october 21 Exploring the Side Effects of Receptor Agonist: To Ensure Its Optimal Positioning What's next for GLP-1 innovation:

Methods for measuring GFR by plasma clearance

PEAK counsels patients to limit or avoid alcohol while taking Contrave

High C-rated LiPo batteries must be handled with care due to their ability to discharge large currents rapidly

Employer coalitions could pool risk, subscription models may spread costs more predictably, and outcomes-based contracts could tie payments to real-world health improvements

"I have my experience with peptides

Pfizer, after discontinuing its initial danuglipron candidate due to safety concerns in April 2025, re-entered the race through a $10 billion acquisition of clinical-stage biotech Metsera in November 2025, securing a next-generation obesity pipeline [43]